- Fatty liver disease, now called MASLD, is driven by insulin resistance and metabolic dysfunction rather than by alcohol in the great majority of cases.
- The best evidence we have for treating it is weight loss and GLP-1 medicines are the most effective weight-loss tools in medicine today.
- Liver enzymes alone understate the problem. A cardiometabolic panel reads the liver inside the whole system rather than as an isolated organ.
- Our $299 monthly membership includes the quarterly Biomarker Audit that tracks the markers that matter and the medicine is billed by the pharmacy at cost.
Fatty liver disease is one of the most common findings on the panels we review and one of the most under-explained in ordinary care. Patients are told their liver enzymes are slightly high and that they should lose some weight. Nobody explains what is actually happening inside the organ, what reverses it and what does not.
We want to close that gap, because fatty liver is treatable, the mechanism is well understood and the same treatment that helps the liver helps everything else on the panel.
What MASLD actually is
MASLD stands for metabolic dysfunction-associated steatotic liver disease. It replaced the older term NASH in most clinical conversation. The name matters less than the mechanism. When insulin resistance is present, the liver stores fat it would otherwise process and over time that fat drives inflammation and scarring in a minority of patients.
The condition travels with a familiar crowd. Rising HbA1c, elevated triglycerides, low HDL, high blood pressure and abdominal fat gain usually arrive together. This is why we read the liver inside the cardiometabolic picture rather than as its own specialty visit.
Why GLP-1 medicines help
The strongest lever against MASLD is meaningful weight loss and nothing in medicine produces it as reliably as the GLP-1 class. In the SURMOUNT-1 trial, tirzepatide produced average weight losses of up to about 22.5 percent over 72 weeks. In STEP 1, semaglutide at 2.4 mg produced average losses of roughly 15 percent. Individual results vary and those are trial averages rather than promises.
What the liver studies show is consistent with that mechanism. Liver fat content falls as body weight falls, often substantially. Liver enzymes improve. In patients with evidence of inflammation and early scarring, histologic improvements have been seen in trials of both semaglutide and tirzepatide. The effect is dose-related to weight loss rather than to any unique liver property of either molecule.
The panel we use to track it
Standard care orders ALT and AST and calls it a day. Those enzymes are noisy, they normalize even when disease progresses and they understate the problem. Our Biomarker Audit reads the liver inside the whole metabolic picture.
| Marker | What it tells us about the liver |
|---|---|
| ALT, AST | Liver cell irritation, useful but incomplete on their own |
| GGT | Often elevated with metabolic liver fat, more specific than ALT alone |
| Fasting insulin, HOMA-IR estimate | The driver of the fat storage in the first place |
| HbA1c | Where blood sugar is heading, which is where the disease is heading |
| Triglycerides, HDL | The lipid fingerprint that travels with liver fat |
| hs-CRP | Whole-body inflammation, including hepatic inflammation |
| ApoB | The cardiovascular risk that runs alongside MASLD |
What reversal actually looks like
Patients deserve a realistic picture rather than a hopeful one. Liver fat falls early and often dramatically, sometimes within weeks of meaningful weight loss. Inflammation follows more slowly. Fibrosis, the scarring stage, is the least reversible, which is exactly why earlier intervention matters more than any later rescue.
In practice, a patient on a GLP-1 who loses twelve percent of their body weight over six months will usually see liver enzymes normalize, fasting insulin fall and triglycerides improve together. Those are the numbers we track at each quarterly audit. If they are all moving the right way, the liver is healing alongside everything else.
Why this is a cardiometabolic conversation, not a liver conversation
A gastroenterologist treats the liver. A cardiometabolic physician treats the system that made the liver sick. The distinction matters because MASLD is not really a liver disease in isolation. It is the liver's report on systemic insulin resistance and treating the insulin resistance is what treats the liver.
Our clinical protocols were built around this system view. The same quarterly panel that tracks your liver also tracks your ApoB, your HbA1c, your hormones and your thyroid, because those are not separate problems that happen in one body. They are one problem with different organs reporting it.
Who we see this in
The patients who arrive with this finding are often the ones their labs called normal. Liver enzymes at the upper edge of the reference range, dismissed. An A1c of 5.9, told to watch it. A triglyceride of 180, called borderline. Each of those numbers is part of a pattern and the pattern is what our panel is built to read.
If you have been told your liver is slightly fatty and nothing more and you want to know whether it is reversible in your case, that answer starts with a full biomarker picture and a clinician who reads it as one system.
Frequently asked questions
What is MASLD?
MASLD stands for metabolic dysfunction-associated steatotic liver disease. It is the current name for what was often called fatty liver disease or NASH and it is driven by insulin resistance rather than alcohol in most cases.
Can GLP-1 medicines reverse fatty liver?
They are the most effective weight-loss tools available and weight loss is the strongest lever against MASLD. Trial evidence shows liver fat falling and liver enzymes improving as weight comes off. In patients with inflammation and early scarring, studies of semaglutide and tirzepatide have shown histologic improvement. Reversal depends on how early the disease is caught.
How much weight loss does the liver need?
Research generally shows liver fat improving meaningfully at around five percent body weight loss, with inflammation and fibrosis responding at higher thresholds. Bigger and earlier losses matter more than later and smaller ones.
Are liver enzymes enough to track it?
No. ALT and AST are noisy and can normalize even as disease progresses. Our panel reads enzymes alongside fasting insulin, HbA1c, triglycerides, GGT, hs-CRP and ApoB as one picture.
Is fatty liver dangerous if my enzymes are normal?
It can be. Enzymes understate the problem in many patients. A normal ALT with insulin resistance and high triglycerides is still a metabolic liver signal worth acting on.
Do I need a liver biopsy?
Usually not. Imaging and biomarkers handle most staging and biopsy is reserved for specific clinical questions. Your clinician will tell you plainly if it ever becomes the right test.
Will insurance cover a GLP-1 for fatty liver?
Coverage varies widely and many plans do not cover weight-management medicines at all. Our model works without insurance, with the doctor at a flat monthly fee and the medicine billed by the pharmacy at cost.
How long does reversal take?
Liver fat often falls within weeks of meaningful weight loss. Inflammation follows over months. Fibrosis is the slowest and least reversible, which is why we prefer to start the panel before the scarring stage.
Related guides
- Cardiometabolic optimization: the definitive guide
- Insulin resistance: the doctor who reads the whole panel
- Medical weight loss
- Direct primary care
Sources
- SURMOUNT-1, tirzepatide weight loss results, Eli Lilly
- STEP 1 trial, once-weekly semaglutide in adults with overweight or obesity, NEJM
- AASLD, MASLD clinical guidance resources
References
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). 2022. pubmed.ncbi.nlm.nih.gov/35658024/
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). 2021. pubmed.ncbi.nlm.nih.gov/33567185/